Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2020-03-25 Audit Report / Informat…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit/loss) for both consolidated and separate financial statements, and identifies the auditor (Samjong KPMG). While it contains financial data, it is a regulatory disclosure of the audit results rather than the full 10-K annual report or a standalone audit report document. Given the structure and content, it fits the 'Audit Report / Information' category as it specifically reports the audit outcome and financial summary. FY 2019
2020-03-25 Korean
기타경영사항(자율공시)
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from JW Pharmaceutical regarding a delay in the submission of their audit report. It is a short, formal announcement explaining that the audit process is not yet complete and that the report will be filed as soon as it is received. Since it does not fit into specific categories like 'Audit Report' (which would be the report itself) or 'Annual Report', and it is a general regulatory disclosure regarding corporate governance/compliance, it falls under the 'Regulatory Filings' (RNS) category. FY 2019
2020-03-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for JW Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), director information, and financial summaries (balance sheets and income statements) to be approved by shareholders. This document is a standard proxy statement/notice of meeting sent to shareholders to solicit votes for the upcoming AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2020-03-10 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation' (참고서류) for JW Pharmaceutical's Annual General Meeting (AGM). It contains detailed information regarding the meeting agenda, including the approval of financial statements, changes to the articles of incorporation, and director/auditor information. It is designed to provide shareholders with the necessary information to exercise their voting rights, which is the definition of a Proxy Solicitation & Information Statement (PSI).
2020-03-10 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a regulatory filing submitted to the Korea Exchange (KRX) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). It explains the company's inability to avoid this date due to audit and operational constraints. As this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, proxy solicitation, or voting results, it falls under the general regulatory filing category.
2020-03-10 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, the total dividend amount, and the scheduled date for the general meeting of shareholders to approve the dividend. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2020-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.